Tirzepatide and Semaglutide: 16-Week Gut Microbiome Signals
Gut microbiome research is the focus of a new exploratory secondary analysis of the OMDOT-1 randomised controlled trial. Published in Diabetes, Obesity & Metabolism on 8 November 2026, the paper compares longitudinal microbial changes associated with tirzepatide, semaglutide and conventional treatment over 16 weeks. The analysis included 36 participants and should be read as an exploratory study, not as evidence that changing the microbiome produces a clinical outcome.
Contents
Gut microbiome findings in this analysis
The gut microbiome is the central research topic in this analysis. gut microbiome appears in the source interpretation, but the reported associations remain exploratory and do not establish causation.
What did the researchers compare?
What did the researchers compare? The gut microbiome analysis used participants from a trial with three groups: tirzepatide, semaglutide and conventional treatment. Faecal samples were collected at five time points across 16 weeks. The researchers used 16S rRNA gene sequencing to examine bacterial composition, then applied statistical models to follow changes over time. The gut microbiome study was adjusted for baseline body mass index, with additional exploratory analyses considering changes in body weight and haemoglobin A1c.
Gut microbiome diversity over 16 weeks
Did overall diversity separate the groups? No significant between-group differences were found for beta diversity, a measure of how communities differ from one another. Alpha diversity increased predominantly in the tirzepatide group, and the authors report a significant time-by-treatment interaction compared with control. These findings describe patterns in the sampled participants. They do not establish that one treatment is preferable for an individual or that a diversity measure is a suitable clinical target.
Gut microbiome bacterial trajectories
Which bacterial trajectories differed? Longitudinal comparisons identified differences relative to control for several genus-level features, including Romboutsia_B, Barnesiella and Ruminococcus_E with both treatments, and Vescimonas with tirzepatide. The reported false-discovery-adjusted threshold was q < 0.05. A genus-level association does not by itself identify a causal mechanism, a beneficial organism or a recommendation for changing diet or treatment.
What did the functional analysis show?
What did the functional analysis show? The team inferred microbial functions with PICRUSt2 and analysed 2,106 predicted enzyme-commission features. Tirzepatide and semaglutide showed broadly similar directions across the longitudinal functional results: 67.1% were concordant, with Pearson r = 0.450 and p < 0.001. Treatment-versus-control comparisons included predicted changes involving energy and carbohydrate metabolism. These are computational predictions, not direct measurements of enzyme activity in every participant.
Why is the 16-week design useful?
Why is the 16-week design useful? Repeated gut microbiome sampling adds a time dimension that a single endpoint cannot provide. It can show whether a microbial feature moves with a treatment period and whether trajectories differ from control. At the same time, the sample was small, the analysis was secondary and exploratory, and 16S sequencing does not resolve every strain or metabolic pathway. The results therefore complement, rather than replace, direct metagenomic and functional measurements.
What remains uncertain?
What remains uncertain? The paper does not show that the observed microbiome patterns cause changes in health, nor that they predict an individual response. The analysis cannot turn predicted functions into proof of altered metabolism. It also does not establish how the findings apply outside the trial population or beyond 16 weeks. The registered trial identifier is jRCT1051240017, which provides a route to the underlying study record.
For laboratory readers, the narrow conclusion is that tirzepatide and semaglutide were associated with partly distinct taxonomic trajectories and broadly similar predicted functional patterns in this exploratory 16-week analysis. The result is a research signal to test with larger cohorts, strain-resolved sequencing and direct functional assays. Peptra Labs provides a separate tirzepatide research context page and a research guide; neither is the study material and this article makes no product-performance claim.
For laboratory readers, the narrow conclusion is that tirzepatide and semaglutide were associated with partly distinct taxonomic trajectories and broadly similar predicted functional patterns in this exploratory 16-week analysis. The result is a research signal to test with larger cohorts, strain-resolved sequencing and direct functional assays. Peptra Labs provides a separate tirzepatide research context page and a research guide; neither is the study material and this article makes no product-performance claim.
Related on Peptra Labs
For laboratory readers, the narrow conclusion is that tirzepatide and semaglutide were associated with partly distinct taxonomic trajectories and broadly similar predicted functional patterns in this exploratory 16-week analysis. The result is a research signal to test with larger cohorts, strain-resolved sequencing and direct functional assays. Peptra Labs provides a separate tirzepatide research context page and a research guide; neither is the study material and this article makes no product-performance claim. tirzepatide research context.
References
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.